Exagen (XGN) risk factors, FY2024 10-K

Risks Related to Our Business and Strategy

1. 01We have a history of losses, we expect to incur net losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability
2. 02In the near-term, we expect that our financial results will depend primarily on sales of our testing products, and we will need to generate sufficient revenue from these testing products to grow our business
3. 03Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses
4. 04If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline
5. 05We may be unable to manage our growth effectively, which could make it difficult to execute our business strategy
6. 06Our commercial success depends upon attaining and maintaining significant market acceptance of our testing products among rheumatologists, patients, third-party payors and others in the medical community
7. 07We may experience limits on our revenue if healthcare providers decide not to order our testing products or if we are otherwise unable to create or maintain demand for our testing products
8. 08The sizes of the markets for our testing products have not been established with precision and may be smaller than we estimate
9. 09We may expend our limited resources to pursue a particular testing product and fail to capitalize on other testing products that may be more profitable or for which there is a greater likelihood of success
10. 10If we are unable to support demand for our current testing products or any of our future testing products or solutions, our business could suffer
11. 11Billing for our testing products is complex, and we must dedicate substantial time and resources to the billing process to be paid for our testing products
12. 12As we introduce new testing products, we will need to add new codes to our billing process as well as our financial reporting systems. Failure or delays in effecting these changes in external billing and internal systems and processes could negatively affect our collection rates, revenue and cost of collecting
13. 13Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed
14. 14If we are unable to maintain or expand our sales and marketing force, as needed, to adequately address our customers’ and future partners’ needs, our business may be adversely affected
15. 15If we are unable to compete successfully, we may be unable to increase or sustain our revenue or achieve profitability
16. 16Developing new testing products involves a lengthy and complex process, and we may not be able to commercialize on a timely basis, or at all, other testing products we are developing
17. 17adversely affect the timing for generating potential revenue from a new testing product and our ability to invest in other products in our pipeline
18. 18If we cannot enter into new clinical study collaborations, our product development and subsequent commercialization could be delayed
19. 19We may acquire businesses or assets, form joint ventures or make investments in other companies or technologies that could harm our operating results, dilute our stockholders’ ownership, increase our debt or cause us to incur significant expense
20. 20The diagnostic industry is subject to rapidly changing technology, which could make our current and future testing products obsolete
21. 21Our failure to maintain relationships or build new relationships with key opinion leaders could materially adversely impact our business and prospects
22. 22If we are sued for errors and omissions or professional liability, we could face substantial liabilities that exceed our resources
23. 23The loss of members of our senior management team or our inability to attract and retain highly skilled scientists, technicians and salespeople could adversely affect our business
24. 24If our sole clinical laboratory facility becomes damaged or inoperable, we are required to vacate our existing facility or we are unable to expand our existing facility as needed, we will be unable to perform our testing services and our business will be harmed
25. 25Our testing process involves the use of sophisticated state-of-the-art equipment that requires precise calibration, and issues affecting such equipment may delay delivery or impact the quality of the test results to rheumatologists or otherwise adversely affect our operations
26. 26Failure in our information technology, telephone or other systems could significantly disrupt our operations and adversely affect our business and financial condition
27. 27Our financial condition, commercialization efforts and results of operations have been and may again in the future be adversely affected by outbreaks of contagious diseases
28. 28Performance issues, service interruptions or price increases by our shipping carrier could adversely affect our business, results of operations and financial condition, and harm our reputation and ability to provide testing services on a timely basis
29. 29Inflation could adversely affect our business and financial results
30. 30We maintain cash deposits in excess of federally insured limits. Adverse developments affecting financial institutions, including bank failures, could adversely affect our liquidity and financial performance
31. 31Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited
32. 32Our term loan contains restrictions that limit our flexibility in operating our business, and if we fail to comply with the covenants and other obligations under our loan agreement, the lenders may be able to accelerate amounts owed under the facility and may foreclose upon the assets securing our obligations
33. 33We are a smaller reporting company and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors

Risks Related to Regulatory and Compliance Matters

1. 34Healthcare policy changes could cause significant harm to our business, operations and financial condition
2. 35Complying with numerous regulations pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties
3. 36We conduct business in a heavily regulated industry. Complying with the numerous statutes and regulations pertaining to our business is expensive and time-consuming, and any failure by us, our consultants or commercial partners to comply could result in substantial penalties
4. 37If we use hazardous materials in a manner that causes contamination or injury, we could be liable for resulting damages
5. 38We have previously and may again in the future be required to modify our business practices, pay fines, incur significant expenses or experience losses due to litigation or governmental investigations
6. 39Any of these circumstances may adversely affect our business, prospects, reputation and results of operations
7. 40The FDA may disagree with our assessment that our AVISE® test products and any other tests we may develop are LDTs eligible for enforcement discretion and determine that such test products are fully subject to active compliance enforcement under the FDCA and FDA regulations
8. 41Planned changes in the way that the FDA regulates tests designed and performed by laboratories like ours could result in delay or additional expense in offering our current tests and tests that we may develop in the future
9. 42The FTC and/or state enforcement or regulatory agencies may object to the methods and materials we use to promote our tests and initiate enforcement against us, which could adversely affect our business and financial condition
10. 43Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could materially and adversely affect our business, results of operations and financial condition
11. 44Failure to comply with HIPAA, the HITECH Act, their implementing regulations and similar comparable state laws and regulations affecting the transmission, security and privacy of health information could result in significant penalties or private litigation
12. 45Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties

Risks Related to our Intellectual Property

1. 46If we are unable to maintain intellectual property protection, our competitive position could be harmed
2. 478,126,654, and foreign equivalents thereof), effective March 22, 2024, and as a result may face increased competition with respect to the portion of our testing products previously protected by these patents
3. 48Certain of our testing products utilize unpatented technology that is publicly available and can be used by our competitors
4. 49Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our AVISE® testing products
5. 50We may not be able to protect our intellectual property rights throughout the world
6. 51The patent protection and patent prosecution for some of our testing products may be dependent on third parties
7. 52be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business
8. 53If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business
9. 54Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
10. 55We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses
11. 56Third-party claims alleging intellectual property infringement may prevent or delay our development efforts
12. 57We may be involved in proceedings to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful
13. 58Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties
14. 59We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties

Risks Related to Our Common Stock

1. 60Our stock price may be volatile, and you may not be able to sell shares of our common stock at or above the price you paid
2. 61Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur could significantly reduce the trading price of our common stock and impair our ability to raise adequate capital through the sale of additional equity securities
3. 62Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management
4. 63Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to control or significantly influence all matters submitted to stockholders for approval
5. 64We have never paid dividends on our capital stock, and we do not anticipate paying dividends in the foreseeable future. Your ability to achieve a return on your investment will depend on appreciation, if any, in the price of our common stock
6. 65An active, liquid trading market for our common stock may not be maintained
7. 66Our failure to meet the continued listing requirements of Nasdaq or The Nasdaq Stock Market LLC could result in a delisting of our common stock
8. 67If securities or industry analysts downgrade our common stock or otherwise issue adverse opinions or commentary regarding our stock or do not publish research or reports about our company, our stock price and trading volume could decline
9. 68We could be subject to securities class action litigation